Tillkännagivande • Jul 07
Vaxart Reports Topline 12-Month Safety Data from the 400-Participant Sentinel Safety Cohort of the Phase 2B Clinical Trial of Its Oral Pill Covid-19 Vaccine Vaxart reported topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. Participants in this safety cohort received Vaxart’s oral pill vaccine (201 participants dosed) or an approved mRNA vaccine (199 participants dosed) targeting the XBB strain of SARS-CoV-2, the virus that causes COVID-19. No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events (AEs) were reported in either arm of the study. Data from the complete study, comprising the 400 dosed participants in the sentinel safety cohort and approximately 5,000 dosed participants in the main cohort, are currently anticipated in 2027. Participants in the main cohort received vaccines targeting the KP.2 viral strain prevalent at the time cohort dosing was initiated. Key topline 12-month results from the 400-participant sentinel safety cohort (201 oral vaccinees and 199 mRNA vaccinees) include: No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher AEs were reported in either the oral pill vaccine or mRNA arms of the trial. The most common AEs in participants receiving the oral pill vaccine were malaise/fatigue (20.9%), headache (18.9%) and anorexia (10.0%). Fewer than 10% of participants experienced any other AE. The most common AEs in participants receiving the mRNA vaccine were injection site pain (60.3%), injection site tenderness (40.2%), malaise/fatigue (35.2%), myalgia/muscle pain (33.2%), and headache (28.6%). Arthralgia, chills, anorexia, nausea, diarrhea, and induration/swelling at the injection site were experienced by between 10-15% of participants. Fewer than 10% of participants experienced any other AE. With respect to the efficacy measure of symptomatic COVID, 33 participants in Vaxart’s oral pill vaccine arm and 30 participants in the injectable mRNA vaccine arm had symptomatic disease. Asymptomatic COVID cases were reported in 12 participants in the Vaxart oral pill arm and 12 in the mRNA vaccine arm. It should be noted that this 400-participant sentinel safety cohort was not powered to determine comparative efficacy between the two arms. Topline data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, are anticipated in 2027. The main cohort is designed and powered to support the planned statistical comparison of safety and relative efficacy outcomes between the two arms. Funding for this award was received under Project NextGen, an initiative by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. Vaxart’s project award through the Rapid Response Partnership Vehicle (RRPV) Consortium is valued at up to $344.8 million. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005. Tillkännagivande • Jul 02
Vaxart, Inc. Announces Board and Committee Changes Vaxart, Inc. announced a resolution to the proxy contest in connection with the Company's 2026 Annual Meeting of Stockholders. Vaxart, Inc. initiated a search for an additional independent director to be conducted within 90 days of the conclusion of the 2026 Annual Meeting. Pursuant to a cooperation agreement between the Company and stockholders Daniel P. Houle, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD, Patrice Raffy, Marc Eustace Pereira and Third Quarter Nominees Pty Ltd., the Company will work with the Stockholder Group to identify a mutually agreeable candidate to be appointed to the Board. The Stockholder Group agreed under the cooperation agreement to withdraw the director nominations of Mr. Houle, Dr. Silverberg and Dr. Wallace in connection with the 2026 Annual Meeting. The cooperation agreement additionally provided for the formation of a Stockholder Engagement Committee and a Clinical and Regulatory Affairs Committee, Board committee refreshment, including the selection of new chairs for the Nominating and Governance and Compensation Committees, the adoption of director stock ownership and resignation policies, as well as certain customary standstill, voting, engagement and other provisions. Tillkännagivande • Jun 25
Vaxart Provides Update to Barda Funding Award for Covid-19 Oral Pill Vaccine Trial Vaxart entered into a contract modification that releases additional funding from BARDA, through a contract with Advanced Technology International, to support continuation of the Company’s ongoing Phase 2b COVID-19 oral pill vaccine candidate and advance the next phase of data analysis. Overall funding available for the trial is now approximately $345 million, a decrease of approximately $116 million from its prior modification, following an approximately 50% reduction in participants enrolled in the trial as the result of a BARDA partial termination ordered on August 5, 2025. Per the Company’s contract with Advanced Technology International, the total funding amount available to Vaxart represents an estimate of the costs that will be incurred in the study as it is currently contemplated. The latest modification allows for the release of approximately $29 million for completion of the trial and exploratory analyses to further evaluate safety and efficacy, enabling Vaxart to conduct deeper analytics from the trial data set. Vaxart intends to report 12-month data from the 400-participant Sentinel Cohort in the coming weeks and 12-month data from the 5,085-participant main cohort in the first half of 2027. Funding for this award was received under Project NextGen, an initiative led by BARDA and the National Institute of Allergy and Infectious Diseases to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Other Transaction Number: 75A50123D00005. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus. Tillkännagivande • Jun 23
Daniel P. Houle Issues an Investor Presentation On June 22, 2026, Daniel P. Houle issued an investor presentation titled “A Case for Change at Vaxart”, and urged the shareholders of Vaxart, Inc to vote for his nominees; Daniel P. Houle, Mark Silverberg, and Matthew M. Wallace. Tillkännagivande • Jun 10
Daniel Houle Issues Letter to Shareholders of Vaxart On June 10, 2026, Daniel P. Houle issued letter to shareholders of Vaxart, Inc., seeking support to vote FOR accountability, transparency, and stockholder value by electing Daniel P. Houle, Mark Silverberg, and Matthew M. Wallace. In addition, Daniel P. Houle stating that the stockholders believe the Company possesses a unique technology platform, but stockholder value has remained compromised due to disappointing performance, declining market value, and insufficient engagement, and they call for restoring confidence, increasing transparency, improving communication, and ensuring stockholder interests are central to decision-making. Further, Daniel P. Houle stating that the nominees bring governance, healthcare, clinical, and operational expertise to strengthen oversight and accountability while supporting strategic partnerships, improved communication of the VAAST platform, rebuilding trust, and establishing committees to enhance regulatory oversight and stockholder relations. Furthermore, Daniel P. Houle in the letter concludes that the campaign is about improvement, accountability, and maximizing stockholder value, urging stockholders to vote for transparency, accountability, and stockholder representation. Tillkännagivande • Jun 09
Daniel P. Houle Provides Information to Shareholders of Vaxart On June 6, 2026, Daniel P. Houle posted a message on Stocktwits. Daniel P. Houle reposted the message on Stocktwits on June 7, 2026, and he anticipates reposting it daily on Stocktwits through the date of Vaxart, Inc.’s annual meeting. Tillkännagivande • May 20
Vaxart, Inc., Annual General Meeting, Jul 16, 2026 Vaxart, Inc., Annual General Meeting, Jul 16, 2026. Tillkännagivande • May 01
Vaxart, Inc. to Report Q1, 2026 Results on May 07, 2026 Vaxart, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026 Tillkännagivande • Apr 24
Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors Vaxart, Inc. announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. In February 2026, he joined Altay Therapeutics as CEO and Board Director, directing the advancement of the company’s pipeline of oral transcription factor therapies. He most recently served as the President and CEO of Oncternal Therapeutics, Inc., where he oversaw the clinical development of a diverse pipeline of first-in-class oncology assets. He also brings vaccine development expertise from his previous role as President of Bavarian Nordic, Inc., where he oversaw the development of cancer, infectious disease, and bioterrorism vaccines. Additionally, Dr. Breitmeyer held senior clinical leadership roles at Eli Lilly and Company and Cadence Pharmaceuticals, where he managed the transition of multiple candidates through the clinical and regulatory process toward successful commercial launch. His board experience includes previous director roles at Zogenix, Inc. and Otonomy, Inc., where he served on Audit and Compensation Committees. Previously, he held the position of President at Bavarian Nordic, Inc. and served as Executive Vice President and Chief Medical Officer at Cadence Pharmaceuticals. Dr. Breitmeyer also served as Vice President of Biotechnology at Eli Lilly and Company, where he was responsible for the corporate biotechnology pipeline. Earlier in his career, he held senior leadership roles at Applied Molecular Evolution and Serono Laboratories, where he led the development of therapies resulting in FDA approvals for Rebif® and Serostim®. Dr. Breitmeyer earned his M.D. and Ph.D. from Washington University School of Medicine. He completed postdoctoral fellowships at Harvard Medical School and the Dana-Farber Cancer Institute, where he also served as a clinical instructor. Tillkännagivande • Apr 18
Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC Vaxart, Inc. announces that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC to issue common stock for gross proceeds of $25,000,000 on April 16, 2026. The Commitment Shares were issued and the Purchase Shares will be issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and/ or Rule 506(b) of Regulation D thereunder. 
